Insilico Medicine Receives $5 Million Payment as AI-Discovered Cancer Drug MEN2501 Enters Phase 1 Trial

Insilico Medicine has announced the successful first-in-human dosing of its AI-discovered cancer drug, MEN2501, in a Phase 1 clinical trial. This achievement marks a key milestone under the company’s licensing agreement with Menarini Group, triggering a $5 million payment to Insilico Medicine. The clinical-stage biotechnology company specializes in using generative artificial intelligence for drug discovery and development.

The MEN2501 program represents a significant step forward in applying AI to oncology therapeutics. The Phase 1 trial aims to evaluate the safety, tolerability, and preliminary efficacy of MEN2501 in patients. The milestone payment from Menarini Group underscores the progress made since entering into the licensing agreement. Further details about the ongoing trial and subsequent steps have not been disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 3, 2026

Author

GOAI